Wolbachia Mosquito Biocontrol

Wolbachia-based mosquito control works by releasing male Aedes aegypti mosquitoes carrying the Wolbachia bacterium. When these males mate with wild females, the resulting eggs don't hatch — suppressing the mosquito population without pesticides or genetic modification. Oxitec, headquartered in the UK but with major operations in Brazil, broke ground on the world's largest Wolbachia production facility in Campinas (April 2025), capable of producing millions of mosquitoes per week.

Brazil is the world's largest testbed for biological mosquito control. Oxitec previously received full commercial biosafety approval in Brazil for its genetically modified 'Friendly Aedes' technology (a separate approach using RIDL gene drive), and is now scaling Wolbachia as a complementary tool. The country recorded nearly a million dengue cases in early 2024, creating urgent demand for novel vector control beyond insecticides — to which Aedes aegypti is increasingly resistant.

The combination of Butantan's single-dose dengue vaccine (upstream defense) and Wolbachia biocontrol (downstream vector suppression) gives Brazil a two-pronged strategy against dengue that no other country has assembled. Both technologies were developed or scaled in Brazil because the disease burden justifies the investment. The Wolbachia approach is also being tested against Zika and chikungunya, making it a platform technology for arbovirus control in the tropics.